Navigation Links
New agent may enhance effectiveness of radiotherapy
Date:5/13/2014

Scientists from The University of Manchester part of the Manchester Cancer Research Centre - have demonstrated the potential of a drug to improve the effectiveness of radiotherapy in stopping tumour growth.

There is increasing interest in using the body's own immune system to attack tumour cells a strategy that can be very effective without the side effects associated with conventional chemotherapy.

Skin cancers have been successfully treated using a topical cream, imiquimod, which recruits immune cells through a molecule known as toll-like receptor 7 (TLR7), a protein that recognises foreign and potentially harmful material.

Previously, researchers in Manchester have shown that they can also stimulate the immune system into generating an immune response against non-skin cancers by injecting an agent similar to TLR7 into the blood.

In collaboration with AstraZeneca and Dainippon Sumitomo Pharma, the Manchester group have looked at another molecule that activates TLR7, known as DSR-6434. Using mouse models of two different types of cancer, they investigated DSR-6434 on its own and in combination with radiotherapy and measured the effect on the primary tumour and the number of secondary tumours in the lungs.

Professor Ian Stratford, from Manchester Pharmacy School who, with Professor Tim Illidge, led the research published in the International Journal of Cancer, said: "We have already seen a strong immune system response from other immunotherapy agents in combination with radiation this new agent appears to be even more potent."

His team showed that administering DSR-6434 together with radiotherapy led to tumour shrinkage and increased long-term survival. They found that the combination treatment also reduced the occurrence of secondary lung tumours.

"It looks like there's good reason to use radiotherapy alongside immunotherapy agents in the treatment of solid tumours. These results strongly suggest that this sort of combination therapy should be evaluated in clinical trials with cancer patients," added Professor Stratford.


'/>"/>

Contact: Ali Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester
Source:Eurekalert

Related medicine news :

1. Pig stomach mucins are effective as anti-viral agents for consumer products
2. Imaging agents predict breast cancer response to endocrine therapy
3. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
4. New substances 15,000 times more effective in destroying chemical warfare agents
5. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
6. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
7. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
8. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
9. Rilpivirine for HIV: Added benefit for single agent proven
10. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
11. Investigational agent targets gene signaling pathways to improve response for patients with CLL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy ... health literacy software tool, and the Cancer Patient Education Network (CPEN), an independent ... today announce a new strategic alliance. , As CPEN’s strategic partner, HLI ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology: